Navigation Links
Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach

Delivery Systems and Specific Molecular Structures Needed for siRNA

Therapeutic Success

LONDON, April 7, 2008 /PRNewswire/ -- Silence Therapeutics plc (AIM:SLN) Europe's leading RNAi-focused biotechnology company, today comments on two recent journal articles: Nature(1) "Sequence-and target-independent angiogenesis suppression by siRNA via TLR3" Mark E. Kleinman, et. al., and Molecules and Cells(2) "Immune Activation by siRNA/Liposome Complexes in Mice is Sequence-Independent: Lack of a Role for Toll-like Receptor 3," Kim et. al. In these two publications, researchers questioned current thinking on the mode of action of siRNA therapeutics suggesting that they work by mechanisms other than via specific gene silencing.

Data published in the Nature article (Kleinman et. al.) have been interpreted in recent days in the lay press as a "Setback for Some RNA-Based Drugs" (New York Times(5)). Silence Therapeutics views the cited Nature paper, and another recent paper in Molecules and Cells(2) as highlighting the need for a functional delivery system to ensure the therapeutic siRNA is able to enter cells and achieve gene silencing.

Both studies further reinforce the importance of chemically modifying siRNA to create molecular structures which do not cause unwanted immune stimulation such as cytokine release and interferon response.

The two new studies support the long-standing development approach of Silence Therapeutics, which has focused its research on developing both a potent RNAi-mediating delivery system (AtuPLEX) and chemically-modified siRNA (AtuRNAi) molecules.

Jeff Vick, CEO of Silence Therapeutics, said, "More than eight years ago, Silence Therapeutics recognized the need for, and pioneered the development of, a functional systemic RNAi delivery system that combines proprietary chemical modification and lipid technologies to achieve efficient intracellular uptake without triggering an immune system response. This approach has allowed us to successfully demonstrate the inhibition of solid tumor growth and the spread of metastases. Silence continues to develop additional delivery technologies to broaden the clinical applications of our promising new class of siRNA therapeutics."

Silence Therapeutics has previously reported in 2006, in two peer reviewed publications in Gene Therapy(3,4), the functional in vivo delivery of different AtuRNAi-lipoplexes (chemically modified siRNA molecules formulated in a proprietary lipid complex). In particular, Silence Therapeutics' AtuPLEX formulation was shown to both avoid immune responses (published data demonstrates lack of activation of interferon-alpha and IL-12) and induce RNAi-mediated gene silencing as demonstrated by the selective inhibition of endogenous target-specific gene expression in vivo. Furthermore, independent publications by Judge(6) and Kim(2) also demonstrate that the chemical modification modality utilized in AtuRNAi obviates an immune response.

These Gene Therapy papers also show that the target-specific knockdown (gene silencing) resulted in the modulation of a specific biochemical signaling pathway containing the target, thus demonstrating the potential therapeutic benefits in certain oncology indications.

The multi-faceted approach that Silence Therapeutics has taken to realize the enormous potential of siRNA therapeutics was substantiated by Dr. Alan Sachs, Vice President for RNA Therapeutics at Merck Research Laboratories, a unit of Merck, who was quoted in the New York Times,(5) saying that "future versions of RNA drugs could be encapsulated in fat globules and chemically modified. That would help the drugs enter cells and keep them from setting off the immune system."

Jeff Vick further commented, "That future is now. This is the exact approach pioneered by Silence Therapeutics. Our current pipeline is based on combining our state-of-the-art AtuRNAi molecules and AtuPLEX drug delivery system. We have strong evidence that the siRNA therapeutics we are developing do enter mammalian cells, are appropriately localized intracellularly, and do act by selectively silencing the specifically targeted gene. We believe by continuing to build on this unique expertise we will achieve our goal of becoming a global leader in the RNAi space."


Kleinman et. al., Nature(1), "Sequence-and target-independent angiogenesis suppression by siRNA via TLR3 | doi: 10.1038/nature06765; Received published online 26 March 2008."

Kim et. al., Molecules and Cells(2), Vol. 24, 247, 2007: "Immune Activation by siRNA/Liposome Complexes in Mice Is Sequence-independent: Lack of a Role for Toll-like Receptor 3 Signalling."

Santel et. al., Gene Therapy(3) 2006 Sep;13(18):1360-70. "RNA interference in the mouse vascular endothelium by systemic administration of siRNA- lipoplexes for cancer therapy."

Santel et. al., Gene Therapy(4) 2006 Aug;13(16):1222-34. "A novel siRNA- lipoplex technology for RNA interference in the mouse vascular endothelium."

New York Times(5), April 2, 2008. "Study is a Setback for Some RNA-Based Drugs."

Adam D. Judge, Gurneet Bola, Amy C.H. Lee, Ian MacLachlan, Molecular Therapy(6) Vol. 13, No. 3, March 2006: "Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo."

Notes to Editors:

About Silence Therapeutics plc (

Silence Therapeutics plc (AIM:SLN) is a leading RNAi company. RNA interference (RNAi) can selectively 'silence' genes linked to the onset of disease.

Silence Therapeutics has developed novel, proprietary short interfering RNA ('siRNA') molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules as they show increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This enables the delivery of siRNA molecules to targeted diseased tissues and cells, whilst increasing their bioavailability and intracellular uptake.

In July 2007, Silence Therapeutics formed a research and development collaboration with AstraZeneca to develop AtuRNAi against five specific targets including those in respiratory indications. The Company's AtuRNAi technology also has been sublicensed to Pfizer through Quark's license to Pfizer of the compound RTP-801i-14 for the treatment of Age-related Macular Degeneration (AMD) and a number of other indications. This compound entered the clinic in early 2007. Silence Therapeutics also has licensed to Quark rights to the AtuRNAi structure for its proprietary compound AKIi-5. This compound is in a Phase I human clinical study for treatment of acute kidney injury. In addition, Silence Therapeutics expects to begin the clinical development of its own proprietary AtuRNAi therapeutic molecules for systemic cancer indications in 2008.

Silence Therapeutics is based in London, UK, and Berlin, Germany, and is listed on AIM.

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
4. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
5. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
6. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
7. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
8. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
9. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
10. Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Southern ... and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice Frueh, ... cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU School ...
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
Breaking Medicine News(10 mins):